

Title (en)
COMPOSITIONS OF VACCINES AND ADJUVANTS AND METHODS FOR THE TREATMENT OF URINARY TRACT INFECTIONS

Title (de)
IMPFSTOFFZUSAMMENSETZUNGEN UND ADJUVANZIEN UND VERFAHREN ZUR BEHANDLUNG VON HARNWEGSINFektIONEN

Title (fr)
COMPOSITIONS DE VACCINS, ADJUVANTS ET MÉTHODES DE TRAITEMENT D'INFECTIONS URINAIRES

Publication
EP 3270962 A4 20180822 (EN)

Application
EP 16765693 A 20160316

Priority

- US 201514660523 A 20150317
- US 201562135092 P 20150318
- US 201514800003 A 20150715
- US 2016022711 W 20160316

Abstract (en)
[origin: WO2016149558A2] This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37°C that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

IPC 8 full level
A61K 39/108 (2006.01); **A61K 9/00** (2006.01); **A61K 31/7016** (2006.01); **A61K 39/00** (2006.01); **A61K 39/02** (2006.01); **A61K 39/39** (2006.01)

CPC (source: EP)
A61K 39/02 (2013.01); **A61K 39/0258** (2013.01); **A61K 39/39** (2013.01); **A61K 2039/55511** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)

- [XP] WO 2015044886 A2 20150402 - SEQUOIA SCIENCES INC [US]
- [A] US 2003199071 A1 20031023 - LANGERMANN SOLOMON [US], et al
- [A] US 2008131466 A1 20080605 - REED STEVEN G [US], et al
- [A] US 2013273149 A1 20131017 - SHAW WALTER A [US], et al
- [A] ANDERSON R C ET AL: "Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 1 January 2010 (2010-01-01), pages 123 - 132, XP026770794, ISSN: 0927-7765, [retrieved on 20090820], DOI: 10.1016/J.COLSURFB.2009.08.022
- [A] RHEA N. COLER ET AL: "Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant", PLOS ONE, vol. 6, no. 1, 26 January 2011 (2011-01-26), pages e16333, XP055030261, DOI: 10.1371/journal.pone.0016333
- [A] C. B. FOX ET AL: "Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19, no. 10, 1 October 2012 (2012-10-01), US, pages 1633 - 1640, XP055286524, ISSN: 1556-6811, DOI: 10.1128/CVI.00235-12
- [A] AYESHA MISQUITH ET AL: "In vitro evaluation of TLR4 agonist activity: Formulation effects", COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 113, 1 January 2014 (2014-01-01), NL, pages 312 - 319, XP055270242, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2013.09.006
- [A] LANGERMANN S ET AL: "VACCINATION WITH FIMH ADHESIN PROTECTS CYNOMOLGUS MONKEYS FROM COLONIZATION AND INFECTION BY UROPATHOGENIC ESCHERICHIA COLI", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 181, 1 February 2000 (2000-02-01), pages 774 - 778, XP002944650, ISSN: 0022-1899, DOI: 10.1086/315258
- [A] HW MILLIE FUNG ET AL: "Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity", JOURNAL OF NANOBIOTECHNOLOGY, BIOMED CENTRAL, GB, vol. 11, no. 1, 21 December 2013 (2013-12-21), pages 43, XP021172581, ISSN: 1477-3155, DOI: 10.1186/1477-3155-11-43
- See references of WO 2016149417A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2016149558 A2 20160922; WO 2016149558 A3 20170323; CN 107405395 A 20171128; CN 107530418 A 20180102;
EP 3270962 A1 20180124; EP 3270962 A4 20180822; EP 3270963 A2 20180124; EP 3270963 A4 20180822; WO 2016149417 A1 20160922

DOCDB simple family (application)
US 2016022977 W 20160317; CN 201680016475 A 20160317; CN 201680016531 A 20160316; EP 16765693 A 20160316;
EP 16765794 A 20160317; US 2016022711 W 20160316